PL2089024T3 - Kombinacja inhibitorów IAP i inhibitorów FLT3 - Google Patents

Kombinacja inhibitorów IAP i inhibitorów FLT3

Info

Publication number
PL2089024T3
PL2089024T3 PL07868853T PL07868853T PL2089024T3 PL 2089024 T3 PL2089024 T3 PL 2089024T3 PL 07868853 T PL07868853 T PL 07868853T PL 07868853 T PL07868853 T PL 07868853T PL 2089024 T3 PL2089024 T3 PL 2089024T3
Authority
PL
Poland
Prior art keywords
combination
inhibitors
iap
flt3
active agents
Prior art date
Application number
PL07868853T
Other languages
English (en)
Inventor
James Douglas Griffin
Leigh Zawel
Original Assignee
Novartis Ag
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Dana Farber Cancer Inst Inc filed Critical Novartis Ag
Publication of PL2089024T3 publication Critical patent/PL2089024T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07868853T 2006-11-28 2007-11-27 Kombinacja inhibitorów IAP i inhibitorów FLT3 PL2089024T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US89108807P 2007-02-22 2007-02-22
PCT/US2007/085579 WO2008067280A2 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors
EP07868853A EP2089024B1 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors

Publications (1)

Publication Number Publication Date
PL2089024T3 true PL2089024T3 (pl) 2011-10-31

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07868853T PL2089024T3 (pl) 2006-11-28 2007-11-27 Kombinacja inhibitorów IAP i inhibitorów FLT3

Country Status (20)

Country Link
US (1) US8492429B2 (pl)
EP (1) EP2089024B1 (pl)
JP (1) JP5394249B2 (pl)
KR (1) KR20090087094A (pl)
AT (1) ATE509629T1 (pl)
AU (1) AU2007325280B2 (pl)
BR (1) BRPI0719543A2 (pl)
CA (1) CA2670498A1 (pl)
CO (1) CO6210722A2 (pl)
EC (1) ECSP099472A (pl)
GT (1) GT200900142A (pl)
IL (1) IL198551A0 (pl)
MA (1) MA30966B1 (pl)
MX (1) MX2009005621A (pl)
NO (1) NO20092417L (pl)
PL (1) PL2089024T3 (pl)
PT (1) PT2089024E (pl)
RU (1) RU2456983C2 (pl)
TN (1) TN2009000206A1 (pl)
WO (1) WO2008067280A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
ES2882855T3 (es) 2008-05-16 2021-12-02 Dana Farber Cancer Inst Inc Inmunomodulación por inhibidores de IAP
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
AU2014301958B2 (en) 2013-06-25 2017-11-16 The Walter And Eliza Hall Institute Of Medical Research Method of treating intracellular infection
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
PE20212153A1 (es) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
AU2003249920A1 (en) 2002-07-02 2004-01-23 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
EP2253614B1 (en) * 2004-04-07 2012-09-19 Novartis AG Inhibitors of IAP
JP5227805B2 (ja) * 2005-12-20 2013-07-03 ノバルティス アーゲー Ｉａｐ阻害剤とタキサン７の組合せ剤
PE20110220A1 (es) * 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
EP2089024B1 (en) 2011-05-18
BRPI0719543A2 (pt) 2014-02-25
CA2670498A1 (en) 2008-06-05
JP2010511059A (ja) 2010-04-08
WO2008067280A2 (en) 2008-06-05
PT2089024E (pt) 2011-08-31
CO6210722A2 (es) 2010-10-20
AU2007325280B2 (en) 2011-03-10
ATE509629T1 (de) 2011-06-15
KR20090087094A (ko) 2009-08-14
US20100056467A1 (en) 2010-03-04
US8492429B2 (en) 2013-07-23
ECSP099472A (es) 2009-10-30
EP2089024A2 (en) 2009-08-19
AU2007325280A1 (en) 2008-06-05
MA30966B1 (fr) 2009-12-01
JP5394249B2 (ja) 2014-01-22
NO20092417L (no) 2009-08-25
WO2008067280A3 (en) 2008-08-07
GT200900142A (es) 2010-06-24
MX2009005621A (es) 2009-06-12
RU2009124590A (ru) 2011-01-10
IL198551A0 (en) 2010-02-17
TN2009000206A1 (en) 2010-10-18
RU2456983C2 (ru) 2012-07-27

Similar Documents

Publication Publication Date Title
IL198551A0 (en) Combination of iap inhibitors and flt3 inhibitors
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
ZA200701629B (en) Gyrase inhibitors and uses thereof
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
HK1176318A1 (en) Injection device
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2007044180A3 (en) Improved toleration iron supplement compositions
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
MX2009005125A (es) Pirrolo[1,2-a]imidazoldiona efectiva en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos.
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
WO2006091222A3 (en) Methods of treating and preventing severe acute respiratory syndrome (sars) with avr118
PL1830833T3 (pl) Połączenie inhibitora transportera glicyny (GLYT1) i środka przeciwpsychotycznego do leczenia objawów schizofrenii jak również sposoby jego wytwarzania oraz zastosowanie
EP1390027A4 (en) COMPOSITION WITH DEMETHYLCANTHARIDINE IN COMBINATION WITH PLATINUM-CONTAINING ANTI-VITAL AGENTS AND THEIR USE